Intervacc AB (publ) announced that the first batch of Strangvac, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.8 SEK | -2.81% | -6.06% | -39.97% |
May. 15 | Intervacc AB Announces Board Appointments | CI |
May. 15 | Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.97% | 28.11M | |
+14.97% | 118B | |
+12.93% | 106B | |
-3.07% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-16.93% | 15.56B | |
+4.77% | 13.63B | |
+28.46% | 12.27B |
- Stock Market
- Equities
- IVACC Stock
- News Intervacc AB
- Intervacc AB Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy